The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Roche Products Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
211 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for OCREVUS ocrelizumab 920 mg/23 mL solution for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ITOVEBI inavolisib 9 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ITOVEBI inavolisib 3 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Roche Products Pty Ltd - Medication transfer set.
-
-
Australian Public Assessment Report (AusPAR)Columvi (glofitamab), with obinutuzumab pretreatment, was provisionally approved for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Columvi is not indicated for the treatment of patients with primary central nervous system lymphoma.
-
Australian Public Assessment Report (AusPAR)Gazyva (obinutuzumab) was approved as a pre-treatment to reduce the risk of cytokine release syndrome (CRS) induced by glofitamab.
-
Prescription medicine registrationActive ingredients: alectinib hydrochloride.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VABYSMO faricimab 120 mg/mL solution for injection in a pre-filled syringe.
-